Health News Summary: US orders 100 million more COVID-19 tests for distribution; Easier-to-produce COVID vaccine shows promise in trials; Nasal spray vaccine booster works in mice and more

0

Here is a summary of health news briefs.

US orders 100 million more COVID-19 tests for distribution

The United States government has purchased more than 100 million additional COVID-19 tests from tester iHealth Lab Inc. as part of the White House’s plan to distribute 500 million free at-home tests across the country, announced Friday the Ministry of Defense. Since January, the US government has allowed households to order four free at-home COVID-19 tests from the COVIDTests.gov website, with delivery expected within seven to 12 days of ordering.

Easier-to-produce COVID vaccine shows promise in trials; Nasal spray vaccine booster works in mice

Here is a summary of some recent studies on COVID-19. They include research that deserves further study to corroborate the findings and that has not yet been certified by peer review. New COVID-19 vaccine could be made like flu shots

US FDA says Empowered Diagnostics is recalling COVID-19 tests

Empowered Diagnostics LLC is recalling its COVID-19 tests because they have not been cleared for use in the United States and could potentially lead to false results, the U.S. Food and Drug Administration (FDA) said Friday. The regulator has labeled the recall of the CovClear COVID-19 Antigen Rapid Test and ImmunoPass COVID-19 Neutralizing Antibody Rapid Test as Class 1, or the most severe type of recall.

Cuban children with disabilities pet jaguars and snakes for therapy

Baby jaguars and an endemic, intricately colored boa known as a “maja” are among the exotic animals at Cuba’s National Zoo that parents and teachers say provide exceptionally effective therapy for children with special needs. Children pet jaguars and play with their paws, stroke the cool, wet skin of snakes and give milk to a zebu cow as part of a program to help people with special needs overcome their fears, said zoo keepers.

Merck’s COVID-19 pill active against Omicron in lab studies

Merck & Co Inc and partner Ridgeback Biotherapeutics said Friday that six laboratory studies have shown their investigational oral COVID-19 drug, molnupiravir, to be active against the fast-spreading Omicron variant. The data assessed the antiviral activity of molnupiravir and other COVID-19 antiviral agents against COVID-19 variants of concern. Molnupiravir has not yet been studied against Omicron in human studies, the companies said.

Regeneron and Sanofi withdraw application to FDA for extension of use of cancer drug

Regeneron Pharmaceuticals Inc and its partner Sanofi have voluntarily withdrawn their application to the US drug regulator for the expanded use of their cancer drug Libtayo in patients with advanced cervical cancer. The request for the monoclonal antibody as a second-line treatment in patients was withdrawn “after the companies and the US Food and Drug Administration were unable to align with certain post-marketing studies”, the companies said on Friday.

South Korea reports 17,542 new COVID cases, new daily record – KDCA

South Korea reported 17,542 new cases of the coronavirus on Friday, another daily record after reporting 16,096 the day before, amid the spread of the highly infectious variant of Omicron, the Korea Control Agency said on Saturday. and disease prevention.

Canada Omicron infections past peak, hospitalizations rising – health official

Canada has passed the worst of the Omicron variant of the coronavirus on some metrics, but Canadians still need to be careful as hospitalizations continue to rise, the country’s top health official said Friday. Omicron infections began to spread rapidly last month, taking over Delta’s dominant variant designation and forcing authorities to impose restrictions on businesses and social gatherings.

Omicron subtype has apparent transmission advantage – UKHSA

The BA.2 subtype of the Omicron coronavirus variant appears to have a substantial growth advantage over the currently predominant BA.1 type, the UK’s Health Security Agency said on Friday. The UKHSA said there was an increased growth rate of BA.2 compared to BA.1 in all areas of England where there were enough cases to compare them, and that “the benefit of apparent growth is currently substantial”.

Britain to start rolling out Pfizer COVID pill next month

Britain will start rolling out Pfizer’s COVID-19 pill to vulnerable people next month, the Department of Health announced on Friday, targeting treatment for people with weakened immune systems for whom the vaccine may be less effective. The Department of Health said Pfizer’s antiviral treatment Paxlovid, a combination of Pfizer’s pill with an older antiviral, ritonavir, will be made available to thousands of people from February 10.

(This story has not been edited by the Devdiscourse team and is auto-generated from a syndicated feed.)

Share.

About Author

Comments are closed.